<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31886839</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>77</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS).</ArticleTitle><Pagination><StartPage>480</StartPage><EndPage>488</EndPage><MedlinePgn>480-488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2019.4490</ELocationID><Abstract><AbstractText Label="IMPORTANCE">A new outcome measure for overall disability level with improved responsiveness is needed for amyotrophic lateral sclerosis (ALS) clinical trials.</AbstractText><AbstractText Label="OBJECTIVE">To describe the creation and development of a new self-reported ALS disability scale with improved item targeting and psychometric properties that used a mathematically rigorous Rasch methodology.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">A preliminary ALS disability questionnaire with 119 questions was created based on literature review, clinical judgement of an expert panel, and patient input. Patients with ALS were recruited from January 2017 to June 2019 from the Emory University and Atlanta VA Medical Center ALS clinics, both in Atlanta, Georgia, during regularly scheduled clinic appointments to complete the draft questionnaire and standard ALS outcome measures. All consecutive patients seen at the Emory University and Atlanta VA Medical Center ALS clinics during the recruitment period with a diagnosis of ALS who were able to provide informed consent were invited to participate in the study. Rasch analyses were performed, and items were systematically removed based on missing data, model fit, disordered thresholds, item bias, and clinical judgment. A total of 509 patients with ALS were seen at the 2 sites during the recruitment period, and 264 patients provided informed consent.</AbstractText><AbstractText Label="INTERVENTIONS">Participants completed the draft Rasch questionnaire and the revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Rasch analyses and standard scale metrics were performed to create the new scale, and Rasch analyses were performed on the ALSFRS-R for comparison.</AbstractText><AbstractText Label="RESULTS">Overall, 243 participants with ALS completed the draft questionnaire, and 230 participants were included for Rasch analyses. The mean (SD) age for study participants was 61.9 (11.1) years, 146 (60.1%) were men, and site of onset was 23.0% bulbar (n&#x2009;=&#x2009;56), 36.2% upper extremity (n&#x2009;=&#x2009;88), and 39.5% lower extremity (n&#x2009;=&#x2009;96). A 28-question Rasch-Built Overall ALS Disability Scale (ROADS) was constructed with each item scored 0, 1, or 2. The ROADS fulfilled Rasch model requirements, demonstrated improved item targeting compared with the ALSFRS-R, and had test-retest reliability of 0.97. Individual question fit statistics demonstrated infit values from 0.68 to 1.37 and outfit values from 0.66 to 1.43. The difference between the empirical variance explained by the measures and the modeled variance was 0.1%. The ALSFRS-R violated Rasch model expectations and demonstrated disordered thresholds for 9 of 12 questions; 13 of 48 answer choices on the ALSFRS-R were never the most probable answer choice for any overall disability level.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, the 28-question, self-reported ROADS, which is linearly weighted, had improved item targeting compared with the ALSFRS-R, had high test-retest reliability, and was validated. ROADS may serve as a valuable and easily accessible outcome measure for use in ALS trials and in the clinic with improved responsiveness compared with the ALSFRS-R.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fournier</LastName><ForeName>Christina N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Atlanta VA Medical Center, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedlack</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Duke University, Durham, North Carolina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lahey Clinic, Burlington, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beckwith</LastName><ForeName>Diane</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaminski</LastName><ForeName>Kathleen H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Atlanta VA Medical Center, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tyor</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Atlanta VA Medical Center, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hertzberg</LastName><ForeName>Vicki</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>James</LastName><ForeName>Virginia</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polak</LastName><ForeName>Meraida</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>IK2 CX001595</GrantID><Acronym>CX</Acronym><Agency>CSRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006233" MajorTopicYN="N">Disabled Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Bedlack reports grants from ALS Association, Motor Neuron Disease Association, Cytokinetics, Orion, and Ultragenyx and personal fees from ALS Association, Mallinkrodt, Biohaven Pharmaceutical, ITF Pharma, Brainstorm Cell Therapeutics, Biogen, New Biotic, Cytokinetics, and Woolsey Pharmaceuticals outside the submitted work. Dr Quinn reports personal fees for serving on the advisory boards of Acceleron Pharma and Amicus Therapeutics outside the submitted work. Dr Tyor reports grants from Atlanta VA Medical Center during the conduct of the study. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31886839</ArticleId><ArticleId IdType="pmc">PMC6990811</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2019.4490</ArticleId><ArticleId IdType="pii">2758019</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mora JS, Genge A, Chio A, et al. ; AB10015 STUDY GROUP . Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2019;1-10. doi:10.1080/21678421.2019.1632346</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Statland JM, Moore D, Wang Y, et al. ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium . Rasagiline for amyotrophic lateral sclerosis: a randomized, controlled trial. Muscle Nerve. 2019;59(2):201-207. doi:10.1002/mus.26335</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26335</ArticleId><ArticleId IdType="pmc">PMC6545236</ArticleId><ArticleId IdType="pubmed">30192007</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG; Writing Group; Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Wolff AA, Meng L, et al. ; BENEFIT-ALS Study Group . A randomized, placebo-controlled, double-blind phase IIb trial evaluating the safety and efficacy of tirasemtiv in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2016;17(5-6):426-435. doi:10.3109/21678421.2016.1148169</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1148169</ArticleId><ArticleId IdType="pubmed">26982815</ArticleId></ArticleIdList></Reference><Reference><Citation>Shibuya K, Misawa S, Kimura H, et al. . A single blind randomized controlled clinical trial of mexiletine in amyotrophic lateral sclerosis: efficacy and safety of sodium channel blocker phase II trial. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):353-358. doi:10.3109/21678421.2015.1038277</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1038277</ArticleId><ArticleId IdType="pubmed">25960085</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, et al. . An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3-4):242-249. doi:10.1080/21678421.2017.1421666</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et al. ; BDNF ALS Study Group (Phase III) . The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21. doi:10.1016/S0022-510X(99)00210-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutkove SB, Caress JB, Cartwright MS, et al. . Electrical impedance myography as a biomarker to assess ALS progression. Amyotroph Lateral Scler. 2012;13(5):439-445. doi:10.3109/17482968.2012.688837</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.688837</ArticleId><ArticleId IdType="pmc">PMC3422377</ArticleId><ArticleId IdType="pubmed">22670883</ArticleId></ArticleIdList></Reference><Reference><Citation>Kollewe K, Mauss U, Krampfl K, Petri S, Dengler R, Mohammadi B. ALSFRS-R score and its ratio: a useful predictor for ALS-progression. J Neurol Sci. 2008;275(1-2):69-73. doi:10.1016/j.jns.2008.07.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2008.07.016</ArticleId><ArticleId IdType="pubmed">18721928</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Liu D, Leitner ML, et al. . Quantitative strength testing in ALS clinical trials. Neurology. 2016;87(6):617-624. doi:10.1212/WNL.0000000000002941</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002941</ArticleId><ArticleId IdType="pmc">PMC4977369</ArticleId><ArticleId IdType="pubmed">27385750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann P, Levy G, Montes J, et al. ; QALS study group . Excellent inter-rater, intra-rater, and telephone-administered reliability of the ALSFRS-R in a multicenter clinical trial. Amyotroph Lateral Scler. 2007;8(1):42-46. doi:10.1080/17482960600888156</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600888156</ArticleId><ArticleId IdType="pubmed">17364435</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier A, Holm T, Wicks P, et al. . Online assessment of ALS functional rating scale compares well to in-clinic evaluation: a prospective trial. Amyotroph Lateral Scler. 2012;13(2):210-216. doi:10.3109/17482968.2011.633268</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2011.633268</ArticleId><ArticleId IdType="pmc">PMC3310482</ArticleId><ArticleId IdType="pubmed">22292842</ArticleId></ArticleIdList></Reference><Reference><Citation>Atassi N, Berry J, Shui A, et al. . The PRO-ACT database: design, initial analyses, and predictive features. Neurology. 2014;83(19):1719-1725. doi:10.1212/WNL.0000000000000951</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000951</ArticleId><ArticleId IdType="pmc">PMC4239834</ArticleId><ArticleId IdType="pubmed">25298304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedlack RS, Vaughan T, Wicks P, et al. . How common are ALS plateaus and reversals? Neurology. 2016;86(9):808-812. doi:10.1212/WNL.0000000000002251</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000002251</ArticleId><ArticleId IdType="pmc">PMC4793781</ArticleId><ArticleId IdType="pubmed">26658909</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson CE, Gronseth G, Rosenfeld J, et al. ; Muscle Study Group . Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve. 2009;39(2):137-143. doi:10.1002/mus.21213</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.21213</ArticleId><ArticleId IdType="pubmed">19145653</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Rutkove SB, Caress JB, et al. . Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8):555-561. doi:10.1080/21678421.2018.1510008</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1510008</ArticleId><ArticleId IdType="pmc">PMC6438779</ArticleId><ArticleId IdType="pubmed">30265154</ArticleId></ArticleIdList></Reference><Reference><Citation>Andres PL, Allred MP, Stephens HE, et al. . Fixed dynamometry is more sensitive than vital capacity or ALS rating scale. Muscle Nerve. 2017;56(4):710-715. doi:10.1002/mus.25586</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.25586</ArticleId><ArticleId IdType="pubmed">28120413</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Hermans MC, Faber CG, Gorson KC, Merkies IS, Thonnard JL; PeriNomS Study Group . Rasch-ionale for neurologists. J Peripher Nerv Syst. 2015;20(3):260-268. doi:10.1111/jns.12122</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12122</ArticleId><ArticleId IdType="pubmed">26115370</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennant A, Conaghan PG. The Rasch measurement model in rheumatology: what is it and why use it? when should it be applied, and what should one look for in a Rasch paper? Arthritis Rheum. 2007;57(8):1358-1362. doi:10.1002/art.23108</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23108</ArticleId><ArticleId IdType="pubmed">18050173</ArticleId></ArticleIdList></Reference><Reference><Citation>van Nes SI, Vanhoutte EK, van Doorn PA, et al. . Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology. 2011;76(4):337-345. doi:10.1212/WNL.0b013e318208824b</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e318208824b</ArticleId><ArticleId IdType="pubmed">21263135</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Faber CG, van Nes SI, et al. ; PeriNomS Study Group . Rasch-built overall disability scale for multifocal motor neuropathy (MMN-RODS(c)). J Peripher Nerv Syst. 2015;20(3):296-305. doi:10.1111/jns.12141</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12141</ArticleId><ArticleId IdType="pubmed">26329270</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto S, de Carvalho M. The R of ALSFRS-R: does it really mirror functional respiratory involvement in amyotrophic lateral sclerosis? Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(1-2):120-123. doi:10.3109/21678421.2014.952641</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.952641</ArticleId><ArticleId IdType="pubmed">25205208</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mandrioli J, Giordano A, Ferro S; ERRALS Group . A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):331-337. doi:10.3109/21678421.2015.1026829</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1026829</ArticleId><ArticleId IdType="pubmed">25916346</ArticleId></ArticleIdList></Reference><Reference><Citation>Franchignoni F, Mora G, Giordano A, Volanti P, Chi&#xf2; A. Evidence of multidimensionality in the ALSFRS-R Scale: a critical appraisal on its measurement properties using Rasch analysis. J Neurol Neurosurg Psychiatry. 2013;84(12):1340-1345. doi:10.1136/jnnp-2012-304701</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-304701</ArticleId><ArticleId IdType="pubmed">23516308</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanhoutte EK, Draak TH, Gorson KC, et al. ; PeriNomS Study Group . Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison. J Peripher Nerv Syst. 2015;20(3):289-295. doi:10.1111/jns.12118</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jns.12118</ArticleId><ArticleId IdType="pubmed">26114893</ArticleId></ArticleIdList></Reference><Reference><Citation>Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ. How responsive is the Multiple Sclerosis Impact Scale (MSIS-29)? a comparison with some other self report scales. J Neurol Neurosurg Psychiatry. 2005;76(11):1539-1543. doi:10.1136/jnnp.2005.064584</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.064584</ArticleId><ArticleId IdType="pmc">PMC1739386</ArticleId><ArticleId IdType="pubmed">16227547</ArticleId></ArticleIdList></Reference><Reference><Citation>Emory University School of Medicine  Emory ALS center. https://med.emory.edu/departments/neurology/programs_centers/emory_als_center/. Accessed November 19, 2019.</Citation></Reference><Reference><Citation>Knudson RJ, Lebowitz MD, Holberg CJ, Burrows B. Changes in the normal maximal expiratory flow-volume curve with growth and aging. Am Rev Respir Dis. 1983;127(6):725-734.</Citation><ArticleIdList><ArticleId IdType="pubmed">6859656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Fitzpatrick R, Brennan C, Bromberg M, Swash M. Development and validation of a short measure of health status for individuals with amyotrophic lateral sclerosis/motor neurone disease: the ALSAQ-40. J Neurol. 1999;246(suppl 3):III16-III21. doi:10.1007/BF03161085</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03161085</ArticleId><ArticleId IdType="pubmed">10631656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenkinson C, Hobart J, Chandola T, Fitzpatrick R, Peto V, Swash M; ALS-HPS Steering Group. Amyotrophic Lateral Sclerosis Health Profile Study . Use of the short form health survey (SF-36) in patients with amyotrophic lateral sclerosis: tests of data quality, score reliability, response rate and scaling assumptions. J Neurol. 2002;249(2):178-183. doi:10.1007/PL00007861</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/PL00007861</ArticleId><ArticleId IdType="pubmed">11985383</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney D, Alexander M, Corr B, O&#x2019;Toole O, Hardiman O. Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(3):150-153. doi:10.1080/14660820410019675</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14660820410019675</ArticleId><ArticleId IdType="pubmed">15512903</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett L, Cano S, Zajicek J, Hobart J. Lending a hand: can DASH items help ABILHAND improve manual ability measurement in multiple sclerosis? Mult Scler. 2015;21(5):612-621. doi:10.1177/1352458514549396</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458514549396</ArticleId><ArticleId IdType="pubmed">25583836</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CC, Bode RK. Psychometric validation of the Manual Ability Measure-36 (MAM-36) in patients with neurologic and musculoskeletal disorders. Arch Phys Med Rehabil. 2010;91(3):414-420. doi:10.1016/j.apmr.2009.11.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apmr.2009.11.012</ArticleId><ArticleId IdType="pubmed">20298833</ArticleId></ArticleIdList></Reference><Reference><Citation>Bacci ED, Wyrwich KW, Phillips GA, Vollmer T, Guo S. Analysis of the psychometric properties of the Multiple Sclerosis Impact Scale-29 (MSIS-29) in relapsing-remitting multiple sclerosis using classical and modern test theory. Mult Scler J Exp Transl Clin. 2016;2:2055217316673235. doi:10.1177/2055217316673235</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2055217316673235</ArticleId><ArticleId IdType="pmc">PMC5433397</ArticleId><ArticleId IdType="pubmed">28607741</ArticleId></ArticleIdList></Reference><Reference><Citation>Linacre JM. Rasch analysis of rank-ordered data. J Appl Meas. 2006;7(1):129-139.</Citation><ArticleIdList><ArticleId IdType="pubmed">16385155</ArticleId></ArticleIdList></Reference><Reference><Citation>Linacre JM. Sample size and item calibration stability. Rasch Meas Trans. 1994;7:328.</Citation></Reference><Reference><Citation>Wyse AE. Scale anchoring with the Rasch Model. J Appl Meas. 2017;18(1):43-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">28453498</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe EW, Smith EV Jr. Instrument development tools and activities for measure validation using Rasch models: part II: validation activities. J Appl Meas. 2007;8(2):204-234.</Citation><ArticleIdList><ArticleId IdType="pubmed">17440262</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe EW, Smith EV Jr. Instrument development tools and activities for measure validation using Rasch models: part I: instrument development tools. J Appl Meas. 2007;8(1):97-123.</Citation><ArticleIdList><ArticleId IdType="pubmed">17215568</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency  Radicava: withdrawal of the marketing authorisation application. https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/radicava. Accessed November 18, 2019.</Citation></Reference><Reference><Citation>Food and Drug Administration 
Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; Availability. Published December 9, 2009. https://www.federalregister.gov/documents/2009/12/09/E9-29273/guidance-for-industry-on-patient-reported-outcome-measures-use-in-medical-product-development-to. Accessed November 18, 2019.</Citation></Reference><Reference><Citation>Northeast Amyotrophic Lateral Sclerosis Consortium  NEALS clinical trials capabilities. https://www.neals.org/for-als-researchers/neals-clinical-trial-capabilities/. Accessed November 20, 2019.</Citation></Reference><Reference><Citation>Al-Chalabi A. ALSFRS-R training: ENCALS: SOP v1.2. Published June 2015. 
https://www.encals.eu/wp-content/uploads/2016/09/ALSFRS-SOP-ENCALS-presentation.pdf. Accessed November 18, 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>